Biotech RadarJobs updated

COMPANY

Vor Biopharma

HQ: Boston, MA source · vorbio.com ↗ · New England

Clinical Phase 3

4 open jobs · last seen Oct 23, 2026 · 13 sources

Profile checked Oct 10, 2026

Keywords: Leukemia, Myeloid, Acute Systemic Lupus Erythematosus Primary Sjogren's Disease Generalized Myasthenia Gravis Myelodysplastic Syndromes Telitacicept VOR33 VCAR33

Since the raise (Mar 27, 2026): 4 of 4 open jobs were first seen after it.

4Open jobs$455.6MRaised (2 yrs)7Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Data ManagerBoston, MAOct 15, 2026Oct 16, 2026
Senior Manager Statistical ProgrammingBoston, MAOct 15, 2026Oct 16, 2026
Director GCP/GVP Inspection Readiness and ManagementBoston, MASep 21, 2026Oct 5, 2026
Director Medical Information – Medical AffairsBoston, MAMay 29, 2026Oct 5, 2026

See all 4 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (4 open jobs at last check). source ↗
  2. Raise Private placement: $75M (total, as published), announced Mar 27, 2026. Source: SEC filing. source ↗
  3. Trial start 3: Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease source ↗
  4. Raise Private placement: $150M (total, as published), announced Dec 15, 2025. Source: SEC filing. source ↗
  5. Raise Private placement: $175M (total, as published), announced Jun 25, 2025. Source: SEC filing. source ↗
  6. Partnership Partnership / licensing: $125M (upfront, as published), announced Jun 25, 2025. Source: SEC filing. source ↗
  7. Raise Private placement: $55.6M (total, as published), announced Dec 27, 2024. Source: SEC filing. source ↗
  8. Trial start Phase 3: A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) source ↗
  9. Trial start Phase 3: A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) source ↗
  10. Trial start Phase 1/Phase 2: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant source ↗
  11. Trial start Phase 3: A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) source ↗
  12. Trial start —: A Long-term Follow-up Study of Patients Who Received VOR33 source ↗
  13. Trial start Phase 1/Phase 2: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 4

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Data ManagerBoston, MAOct 15, 2026Oct 16, 2026Not stated
Senior Manager Statistical ProgrammingBoston, MAOct 15, 2026Oct 16, 2026Not stated
Director GCP/GVP Inspection Readiness and ManagementBoston, MASep 21, 2026Oct 5, 2026Senior
Director Medical Information – Medical AffairsBoston, MAMay 29, 2026Oct 5, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $455.6M. Last 2 years.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT07404865Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease3RecruitingFeb 26, 20262028-12 (estimated)
NCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Phase 3RecruitingJul 17, 20242027-05 (estimated)
NCT06456567A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)Phase 3Withdrawn2024-09Jan 2, 2025 (actual)
NCT05306574A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)Phase 3TerminatedJun 20, 2022Jan 6, 2025 (actual)
NCT05309733A Long-term Follow-up Study of Patients Who Received VOR33Not listedTerminatedApr 15, 2022May 28, 2025 (actual)
NCT05984199Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell TransplantPhase 1/Phase 2TerminatedDec 11, 2023May 28, 2025 (actual)
NCT04849910Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSPhase 1/Phase 2TerminatedDec 16, 2021May 28, 2025 (actual)
Feedback